Article · 31 Dec 2025
Mini reviewPublished 29 Apr 2023
AAV-based Fusion Protein Targeting Human VEGFR-2 Domains Shows Promise in Treating Neovascular- Associated Retinal Diseases in Mice
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Neovascular-associated retinal diseases, including age-related macular degeneration and diabetic retinopathy, are leading causes of vision loss worldwide. Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) plays a critical role in angiogenesis, making it an attractive therapeutic target for these diseases. In this study, we developed an Adeno-Associated Virus (AAV)-based fusion protein specifically targeting human VEGFR-2 domains to evaluate its efficacy in treating neovascular-associated retinal diseases in mice. The AAV-based fusion protein was designed to consist of a Single-Chain Antibody Fragment (scFv) derived from a high-affinity VEGFR-2 antibody, fused with a potent anti-angiogenic peptide. The scFv component enabled specific binding to VEGFR-2, while the anti-angiogenic peptide aimed to inhibit downstream signaling pathways involved in angiogenesis. The fusion protein was packaged into an AAV vector for efficient delivery to retinal cells.
Subjects
Oncology & CancerSurgeryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Archives of Surgical Oncology.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives of Surgical Oncology
- SubjectOncology & Cancer
- SubjectSurgery
- BylineArticles whose byline prints “Yin Cao”
